Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841, and highlights hair multiplication research from Koehler Lab at Harvard. Users express optimism about future advancements.

The user has been using oral finasteride, topical minoxidil, and a dermaroller for hair regrowth, noticing most improvement between months 3 and 4. Other users commented on the positive results and shared their own treatment routines.

A user shared their progress with hair loss treatment using 0.1% topical finasteride for 5 months and 6% minoxidil for 2 months, reporting reduced hair shedding, less scalp visibility, and healthier hair. They experienced no significant side effects except initial itching and dandruff, and noted an increase in libido.

The user is experiencing worsening hair loss despite using oral finasteride, oral minoxidil, microneedling, keto shampoo, and supplements for seven months. They are concerned about continued shedding and lack of regrowth, and are considering adding topical minoxidil to their routine.

Some users experience worsening hair loss with dutasteride and improvement after switching back to finasteride, while others find better results with dutasteride. The effectiveness of treatments like finasteride, dutasteride, minoxidil, and RU58841 varies, requiring individuals to try different combinations or dosages to find what works best.

The user started using 2.5 mg Minoxidil and 1.5 mg Finasteride five months ago, experienced initial shedding, saw progress, but is now concerned about recent hair loss. Another user reassures them that shedding is normal and suggests continuing the treatment.

The conversation is about finding online pharmacies to obtain tretinoin for hairline improvement, with suggestions including Amazon and nurx.com. Alternatives like adapalene are also mentioned.

The conversation is about hair loss treatment progress using oral finasteride, topical minoxidil, and microneedling. Users discuss experiencing shedding phases and the importance of trusting the process for hair regrowth.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also inquires about the timeline for the GT20029 phase 3 trial by Kintor.

KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.

The user shared progress photos after using minoxidil 2.5mg and dutasteride 0.5mg daily for hair growth, starting in summer 2024. They reported no noticeable side effects and confirmed androgenetic alopecia in 2024.

KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.

PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.

The user experienced hair loss since 2021, tried various treatments, and is currently using oral minoxidil and finasteride since December 2024. They are experiencing shedding, which is common when starting or stopping treatments, and are advised to continue the current regimen as it may stabilize over time.

Han Bio plans to start Phase 1 clinical trials for a hair growth treatment in 2027 after successful results in mice. Many users express skepticism about the effectiveness of treatments that work on mice but not on humans, and discuss existing treatments like finasteride and minoxidil.

The user is using a routine involving microneedling, Minoxidil with tretinoin, a red light cap, scalp massages, Nizoral shampoo, and essence oil shampoo to address hair loss, with visible progress noted. They are considering topical finasteride or dutasteride if progress slows but are cautious due to past side effects.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

The user is experiencing a difficult shedding phase after starting a hair loss treatment with oral finasteride, topical minoxidil, and microneedling. Despite the shedding, they remain hopeful for regrowth and plan to continue the treatment, encouraged by others' positive results.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

KX-826 is undergoing Phase III trials in China as a potential treatment for male pattern baldness, with some users considering it as an alternative or addition to finasteride and dutasteride. Opinions on its effectiveness vary, with some users reporting positive results and others finding it expensive and ineffective.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

The user started using minoxidil and finasteride for hair loss treatment six months ago, with some improvement in mental health and manageable side effects. They are considering switching minoxidil brands due to dissatisfaction and are focusing on stress management and lifestyle changes to improve scalp health.

The user is using Dutasteride, Minoxidil, microneedling, RU58841, and tretinoin for hair loss. They are experiencing shedding but notice new hair growth and are curious about the timing of future shedding phases.

The user experienced hair regrowth and strengthening using finasteride, minoxidil, micro-needling, Nizoral, and biotin products. Despite progress, they acknowledge that a hair transplant may be needed for full hairline restoration.

The conversation discusses the challenges and experiences of using minoxidil, finasteride, and dutasteride for hair loss, focusing on the shedding phase and its impact on hair appearance. Users share their personal experiences, side effects, and hopes for improvement, with some considering or having undergone hair transplants.

KX-826 failed Phase III trials due to high placebo effects, patient compliance issues, COVID-19 side effects, and detection method deviations. KX-826 is now marketed as a cosmetic and approved for combination with Minoxidil.

The user is currently using 0.025% Pantostin but plans to switch to 0.1% Alfatradiol. They will also use high-dose Kx826, high-dose Minoxidil, and aggressive microneedling for hair regrowth.

The user experienced hair shedding with finasteride and found minoxidil helpful for regrowth but insufficient alone. They are considering dutasteride but are concerned about potential shedding similar to their experience with finasteride.

A user shared progress pictures showing thicker hair after 8 months of using Fin/Min spray from HIMS. The conversation includes skepticism and humor from other users.